EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR

被引：19

作者：

Wang, Anbang ^{[1
]}

Jiang, Aimin ^{[1
]}

Gan, Xinxin ^{[1
]}

Wang, Zheng ^{[1
]}

Huang, Jinming ^{[1
]}

Dong, Kai ^{[1
]}

Liu, Bing ^{[1
]}

Wang, Linhui ^{[1
]}

Chen, Ming ^{[1
]}

机构：

[1] Naval Med Univ, Changzheng Hosp, Dept Urol, Shanghai 200003, Peoples R China

来源：

BIOMED RESEARCH INTERNATIONAL | 2020年 / 2020卷

基金：

中国国家自然科学基金;

关键词：

METASTATIC UROTHELIAL CARCINOMA; LONG NONCODING RNA; GROWTH;

D O I：

10.1155/2020/6665974

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Long noncoding RNAs play an essential role in bladder cancer progression. The role of long noncoding RNA EGFR-AS1 in bladder cancer needs further study. We used clinical specimens to analyze the relationship between EGFR-AS1 and bladder cancer patients' characteristics. The functional experiments and mechanism studies were performed using qRT-PCR, transwell assay, survival analysis, and correlation analysis. We found that high expression of EGFR-AS1 was nearly related to aggressive bladder cancer and indicated poor prognosis for patients. The functional experiments in vivo and in vitro suggested that EGFR-AS1 promoted the proliferation and invasion of bladder cancer cells. Mechanically, EGFR-AS1 promoted the expression of EGFR by inhibiting the degradation of EGFR mRNA, thereby promoting the metastasis of bladder cancer. In addition, EGFR-AS1/EGFR may be involved in the immune-related pathways of bladder cancer. These studies indicate that the EGFR-AS1/EGFR pathway may be a potential diagnostic marker and therapeutic target for bladder cancer.

引用

页数：9

共 15 条

[11] Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results [J].

Sharma, Padmanee ;

Siefker-Radtke, Arlene ;

de Braud, Filippo ;

Basso, Umberto ;

Calvo, Emiliano ;

Bono, Petri ;

Morse, Michael A. ;

Ascierto, Paolo A. ;

Lopez-Martin, Jose ;

Brossart, Peter ;

Rohrberg, Kristoffer ;

Mellado, Begona ;

Fischer, Bruce S. ;

Meadows-Shropshire, Stephanie ;

Saci, Abdel ;

Callahan, Margaret K. ;

Rosenberg, Jonathan .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (19) :1608-1616

[12]

Siegel R.L., 2018, CA-CANCER J CLIN, V68, P7, DOI [10.3322/caac.21442, DOI 10.3322/CAAC.21442]

[13] Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma [J].

Tan, Daniel S. W. ;

Chong, Fui Teen ;

Leong, Hui Sun ;

Toh, Shen Yon ;

Lau, Dawn P. ;

Kwang, Xue Lin ;

Zhang, Xiaoqian ;

Sundaram, Gopinath M. ;

Tan, Gek San ;

Chang, Mei Mei ;

Chua, Boon Tin ;

Lim, Wan Teck ;

Tan, Eng Huat ;

Ang, Mei Kim ;

Lim, Tony K. H. ;

Sampath, Prabha ;

Chowbay, Balram ;

Skanderup, Anders J. ;

DasGupta, Ramanuj ;

Iyer, N. Gopalakrishna .

NATURE MEDICINE, 2017, 23 (10) :1167-+

[14] Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer [J].

Wang, Anbang ;

Bao, Yi ;

Wu, Zhenjie ;

Zhao, Tangliang ;

Wang, Dong ;

Shi, Jiazi ;

Liu, Bing ;

Sun, Shuhan ;

Yang, Fu ;

Wang, Linhui ;

Qu, Le .

CELL DEATH & DISEASE, 2019, 10 (3)

[15]

Zhou TY, 2016, METHODS MOL BIOL, V1402, P199, DOI 10.1007/978-1-4939-3378-5_16

← 1 2 →